Bimatoprost

Between poor patient adherence and the inherent IOP peaks and troughs associated with eye drop-managed glaucoma, sustained-release medications are greatly needed, a presenter at the virtual OSN New York meeting said.

In this video perspective, E. Randy Craven, MD, associate professor of ophthalmology at Wilmer Eye Institute-Bethesda, discusses his regimen for implanting the Durysta (bimatoprost implant) from Allergan.

Nicox has enrolled the first 12 patients in a phase 3 clinical trial evaluating NCX 470, a novel second-generation nitric oxide-donating bimatoprost analog.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.

SAN FRANCISCO — A study showed Bimatoprost sustained-release implant was noninferior to timolol and may potentially provide sustained IOP control for patients with open-angle glaucoma or ocular hypertension, according to a speaker here.

SAN FRANCISCO — At the American Academy of Ophthalmology annual meeting, E. Randy Craven, MD, discusses a study showing the long-term IOP-lowering effect of the Bimatoprost SR implant from Allergan.

Nicox’s second generation nitric oxide-donating bimatoprost analog NCX 470 met the primary endpoint of non-inferiority compared with latanoprost 0.005% in a dose-ranging study, according to a company press release.